Zuhal Karali

Dr. Zuhal Karali

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
SCSukru Cekic
Sukru Cekic
ZKZuhal Karali
Zuhal Karali
FÇFatih Çiçek
Fatih Çiçek
YCYakup Canıtez
Yakup Canıtez
NSNihat Sapan
Nihat Sapan
Cekic S, et al. J Korean Med Sci. 2021 Nov;36(49):e339. https://doi.org/10.3346/jkms.2021.36.e339

29 December 2022 in Journal of Asthma
Verified
Journal Article
Closed access
SCSukru Cekic
Sukru Cekic
ZKZuhal Karali
Zuhal Karali
YCYakup Canıtez
Yakup Canıtez
SESelin Esmen
Selin Esmen
HOHATİCE ORTAC
HATİCE ORTAC
NSNihat Sapan
Nihat Sapan
Many studies have shown that increased health literacy (HL) improves the management of chronic diseases. Data on the HL levels of adolescents with asthma are limited. In this study, we aimed to inv...

1 December 2020 in Uludağ Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
SCSukru Cekic
Sukru Cekic
YCYakup Canıtez
Yakup Canıtez
ZKZuhal Karali
Zuhal Karali
BKBerke Can Kavuklu
Berke Can Kavuklu
IGİ̇̇lker Gökay Güney
İ̇̇lker Gökay Güney
NSNihat Sapan
Nihat Sapan
Anafilaksi ani gelişen ve hayatı tehdit edebilen bir aşırı duyarlılık reaksiyonudur. Erken tanı ve adrenalinin erken uygulanması mortaliteyi azaltmaktadır. Bu çalışmada tıp eğitiminin son yılında bulunan öğrencilerin anafilaksi hakkındaki bilgi düzeylerinin ölçülmesi amaçlanmıştır. Anket formu; anafilaksi etiyolojisi, tanısı, tedavisi ve korunma yöntemleri ile ilgili 14 sorudan oluşturuldu. Çevrimiçi anket formu tıp fakültesi son sınıfta bulunan 354 öğrenciye internet aracılığıyla gönderildi. Anket formu gönderilen öğrencilerin %44,9’u (n=159) çalışmaya katıldı. Öğrencilerin kız erkek oranı 1,4 (93/66) ve ortalama yaşları 24,8 ±1,5 yıl (ortanca: 25 yıl, en az: 23, en çok: 33) idi. Öğrencilerin aldıkları toplam puanları yüz üzerinden skorlandığında ortalama skor 71,7±12,9’du (ortanca: 71,4, en az: 35,7, en çok: 92,9). Kadın öğrencilerin ortanca skorları (ortanca: 78,6, en az: 35,7, en çok: 92,9), erkek öğrencilerden (ortanca: 71,4, en az: 35,7, en çok: 92,9) anlamlı olarak yüksekti (p=0,011). Adrenalin otoenjektör uygulamasıyla ilgili eğitim aldığını ifade eden öğrencilerin ortanca skorları (ortanca: 78,6, en az: 35,7, en çok: 92,9), almadıklarını ifade edenlerden (ortanca: 71,4, en az: 35,7, en çok: 92,9) anlamlı olarak yüksekti (p

23 May 2023 in Clinical Immunology
Verified
Journal Article
Closed access
ZKZuhal Karali
Zuhal Karali
YKYasin Karali
Yasin Karali
SKSara Sebnem Kilic
Sara Sebnem Kilic

6 October 2026 in Uludağ Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
YKYasin Karali
Yasin Karali
ZKZuhal Karali
Zuhal Karali
HTHatice Zeynep Terzi
Hatice Zeynep Terzi
OM-85 is an immunomodulatory agent used for the prevention of recurrent respiratory tract infections (RTIs) in children; however, the influence of allergic and immunological characteristics on treatment response remains unclear. This study evaluated changes in infection frequency before and after OM-85 treatment and examined whether treatment response was associated with allergic status or immunological characteristics. This single-center, retrospective cohort study included 114 children treated with OM-85 for recurrent RTIs. Annual upper (URTI) and lower (LRTI) respiratory tract infection episodes before and after treatment were compared. Treatment responses were analyzed according to atopic status, inhalant allergen sensitization, and immunoglobulin status (normal, transient hypogammaglobulinemia, and partial IgA deficiency). Independent predictors of post-treatment infection burden were assessed using multivariable linear (ANCOVA) and negative binomial regression analyses. The median age was 56.5 months; 46.5% of patients were atopic, 28.1% had partial IgA deficiency, and 8.8% had transient hypogammaglobulinemia. Following OM-85 treatment, median annual URTI episodes decreased from 8 to 5 (40.6%; p<0.001; r=0.78), and LRTI episodes from 1 to 0 (63.2%; p<0.001; r=0.54). The proportion of children with frequent URTIs (≥6/year) declined from 84.2% to 33.3%, and those with at least one LRTI episode from 60.5% to 32.5%. The reduction was significant in both atopic and non-atopic patients and in subgroups with normal or low immunoglobulin levels. In multivariable analysis, the only independent predictor of post-treatment burden was baseline infection burden. OM-85 treatment was associated with a reduction in both upper and lower respiratory tract infection frequency independently of allergic status and serum immunoglobulin level, with baseline infection burden being the factor most strongly associated with post-treatment infection burden. The greatest clinical benefit is expected in children with frequent infections, and this group may constitute a priority target population for this preventive strategy.

11 September 2026 in Pediatric Allergy, Immunology, and Pulmonology
Verified
Journal Article
Closed access
MKMerve Demirbag Karaali
Merve Demirbag Karaali
SRSimpel Pantir Retzep
Simpel Pantir Retzep
ZKZuhal Karali
Zuhal Karali
YKYasin Karali
Yasin Karali
EYElif UZ YILDIRIM
Elif UZ YILDIRIM
SCSukru Cekic
Sukru Cekic
Introduction:: Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic condition characterized by recurrent episodes of localized tissue swelling, often affecting the skin, upper respiratory tract, and gastrointestinal system. HAE-FXII, also known as HAE with normal C1 inhibitor ( C1INH ), has been associated with mutations in only one of several genes, including FXII encoding coagulation factor XII (FXII). The aim of the study was to investigate the pathogenicity and functional consequences of the c.1681-7G>A intronic variant in the FXII gene according to ACMG guidelines in familial cases of HAE-FXII. Materials and Methods:: Genetic analysis was performed using Sanger sequencing on affected individuals. To assess whether the variant affects splicing, in silico analysis and Messenger RNA (mRNA) studies were conducted on patient-derived samples. Results:: The c.1681-7G>A variant was identified in multiple individuals from affected families. However, splicing analysis revealed that this intronic variant did not cause any alteration in mRNA processing. No aberrant transcripts were detected, and expression levels were comparable to controls, indicating that the variant does not have an effect on splicing or gene function. Discussion:: The c.1681-7G>A variant in the FXII gene is unlikely to be a pathogenic alteration in HAE type III. Contribution to the Literature:: These findings support its classification as a benign variant, emphasizing the importance of functional validation when interpreting intronic changes in genetic diagnostics.